Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
All right. Hello, and welcome. My name is Michael Schmidt. I am one of the biotech analysts at Guggenheim. And it is my great pleasure to welcome Ian Taylor, Chief Scientific Officer of Arvinas. It's a great pleasure to host you, Ian, and thanks for joining us.
My pleasure. Thanks for the invitation.
Questions & Answers
All right, super. So we'll just jump in into Q&A. Ian, Arvinas has obviously been one of the key innovators in the TPD space and also the first company to advance a degrader program into clinical development. One thing that we get asked a lot is -- and now that there's more activity in this category -- how proprietary is the TPD technology, the PROTAC technology, and how high are barriers to entry as we see more and more programs emerge?
Yeah,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
